Enclomiphene keeps coming up in Oregon men’s health clinics, usually framed as testosterone therapy without the needle. That is not quite what it is, and the difference is the whole point.
What it actually does
TRT adds testosterone from outside. Enclomiphene does the opposite: it gets your own testes to make more.
It is a selective estrogen receptor modulator. Your hypothalamus monitors estrogen as its main feedback signal for how much testosterone is around. Enclomiphene blocks that receptor at the hypothalamus, so your brain reads the level as low and increases LH and FSH output. Your testes respond by producing more testosterone, and the machinery for sperm production keeps running instead of shutting down.
It is the purified isomer of clomiphene, a fertility drug used off-label in men for years. The purification matters because the two isomers do opposite things. Enclomiphene is the estrogen antagonist that produces the effect you want. Zuclomiphene behaves as an estrogen agonist and, per the FDA label for clomiphene, stays detectable in the body for longer than a month. Separating them out was the entire rationale for developing enclomiphene on its own, though it is worth being precise: that the leftover isomer explains most of clomiphene’s side effects is the accepted reasoning, not a directly measured finding.
Where it fits, and where it does not
- It needs a working pituitary and working testes. Enclomiphene raises the signal. If your testes cannot respond to that signal, which is primary hypogonadism, it will do nothing. A provider distinguishes the two with LH and FSH on your baseline labs, which the Endocrine Society guideline recommends measuring for exactly this reason.
- Your ceiling is your own production. TRT can put you anywhere on the reference range. Enclomiphene can only get you as high as your own testes can go. In the phase 3 trial, that was enough to carry most men past 400 ng/dL by week four, but for some it is not enough.
- It preserves fertility and testicular size. This is the reason most men choose it, and it is the clearest finding in the research. In a 256-man trial comparing it head to head with testosterone gel, 63.5 percent of men on enclomiphene ended with both a normal testosterone and a sperm concentration at or above 10 million per milliliter, against 24.7 percent on the gel. See our piece on TRT and fertility for why that matters more than men expect.
- It is oral and daily. No injections, no cream, no transfer risk to your family.
The regulatory part nobody explains
Enclomiphene is not FDA approved. A branded version, Androxal, went through phase 3 trials and received a Complete Response Letter from the FDA in December 2015, with the agency citing a study design that no longer demonstrated clinical benefit. It was never approved, so what men actually receive comes from compounding pharmacies. That is legal and common, but it means no FDA-reviewed labeling, and product consistency depends on the pharmacy. Ask which pharmacy your clinic uses and whether it is a 503A or 503B facility.
Side effects to know about
Mood changes are the most commonly reported, and they are the reason to check in early rather than at the ninety day mark. Headache, nausea, and rare visual disturbances such as floaters or blurring also show up. Visual symptoms are a stop-and-call-your-provider event, not a wait-and-see one. Estradiol usually rises alongside testosterone, which is expected and is not automatically a problem.
Reasonable questions to ask
- Are my LH and FSH consistent with secondary hypogonadism, meaning enclomiphene can work for me at all?
- What testosterone number are we targeting, and what do we do if my own production tops out below it?
- How soon do we recheck labs, and how soon do we check in about mood?
- Which compounding pharmacy, and what does it cost monthly compared to injectable testosterone?
Related reading
- TRT in Oregon: What Men Should Know Before Starting
- Low Testosterone: Symptoms, Causes, and What Actually Works
- Natural Testosterone Support Before TRT
References
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PubMed
- Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. PubMed
- Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. 2013;112(8):1188-1200. PubMed
- US Food and Drug Administration. CLOMID (clomiphene citrate) prescribing information, on the relative half-lives of the zuclomiphene and enclomiphene isomers. accessdata.fda.gov
- Repros Therapeutics Inc. Repros Therapeutics receives Complete Response Letter from FDA for enclomiphene. December 1, 2015. SEC EDGAR
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed
Educational content only, not medical advice. Talk to your clinician before making changes.
